- Home
- Publications
- Publication Search
- Publication Details
Title
Immune-checkpoint inhibitors: long-term implications of toxicity
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-26
DOI
10.1038/s41571-022-00600-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma
- (2021) Taigo Kato et al. OncoImmunology
- Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series
- (2021) Ioana A. Dobre et al. Clinical Lung Cancer
- The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6,596 patients
- (2021) S. Street et al. ANNALS OF ONCOLOGY
- Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
- (2021) C.N. Owen et al. ANNALS OF ONCOLOGY
- Effect of dermatological consultation on survival in patients with checkpoint inhibitor‐associated cutaneous toxicity
- (2021) L.L. Thompson et al. BRITISH JOURNAL OF DERMATOLOGY
- Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy
- (2021) Selina K. Wong et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Thyroid immune-related adverse events following immune checkpoint inhibitor treatment
- (2021) Christopher A Muir et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
- (2021) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
- (2021) Daniel J. Olson et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Inhibitor–related Guillain-Barré Syndrome
- (2021) Jorien B.E. Janssen et al. JOURNAL OF IMMUNOTHERAPY
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- (2021) Alexander M M Eggermont et al. LANCET ONCOLOGY
- The changing landscape of atherosclerosis
- (2021) Peter Libby NATURE
- CD4+ T cells are essential for the development of destructive thyroiditis induced by anti–PD-1 antibody in thyroglobulin-immunized mice
- (2021) Yoshinori Yasuda et al. Science Translational Medicine
- Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma
- (2021) J. Randall Patrinely et al. JAMA Oncology
- Obesity results in adipose tissue T cell exhaustion
- (2021) Cara E. Porsche et al. JCI Insight
- Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
- (2021) M. Guida et al. ESMO Open
- Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy
- (2021) Xue Bai et al. CLINICAL CANCER RESEARCH
- Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
- (2021) Helen Dearden et al. EUROPEAN JOURNAL OF CANCER
- Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study
- (2021) Martin Salzmann et al. EUROPEAN JOURNAL OF CANCER
- Metabolic disease and adverse events from immune checkpoint inhibitors
- (2021) Amanda Leiter et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
- (2021) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
- (2021) Miles C. Andrews et al. NATURE MEDICINE
- Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer
- (2021) Ajeeth K. Pingili et al. Cell Reports
- Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
- (2021) Amanda C Guidon et al. Journal for ImmunoTherapy of Cancer
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
- (2021) Julie R Brahmer et al. Journal for ImmunoTherapy of Cancer
- FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma
- (2021) F. Dimitriou et al. ANNALS OF ONCOLOGY
- Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
- (2021) Briana Rose Halle et al. Journal for ImmunoTherapy of Cancer
- Predominance of central memory T cells with high T-cell receptor repertoire diversity is associated with response to PD-1/PD-L1 inhibition in Merkel cell carcinoma
- (2020) Ivelina Spassova et al. CLINICAL CANCER RESEARCH
- Neurologic complications of immune checkpoint inhibitors
- (2020) Alexandra M Haugh et al. Expert Opinion On Drug Safety
- Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
- (2020) Allison Betof Warner et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study
- (2020) Frank B. Cortazar et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- (2020) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature
- (2020) Vivek Kumar et al. ONCOLOGIST
- Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α
- (2020) Liku B Tezera et al. eLife
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
- (2020) Alexander M. M. Eggermont et al. JAMA Oncology
- Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
- (2020) Alessio Cortellini et al. EUROPEAN JOURNAL OF CANCER
- Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis
- (2020) Eleftheria Chorti et al. EUROPEAN JOURNAL OF CANCER
- Early T cell infiltration is modulated by programed cell death-1 protein and its ligand (PD-1/PD-L1) interactions in murine kidney transplants.
- (2020) Young Jun Shim et al. KIDNEY INTERNATIONAL
- Immune Checkpoint Inhibitor‐Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis
- (2020) Virginie Grouthier et al. ONCOLOGIST
- Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
- (2020) Charles Dolladille et al. JAMA Oncology
- COVID-19 and immune checkpoint inhibitors: initial considerations
- (2020) Ryan J Sullivan et al. Journal for ImmunoTherapy of Cancer
- Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors
- (2020) Ohad Oren et al. AMERICAN JOURNAL OF CARDIOLOGY
- Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
- (2020) J. Haanen et al. ANNALS OF ONCOLOGY
- Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort
- (2020) Janet Roberts et al. AUTOIMMUNITY REVIEWS
- Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities
- (2020) Yves Allenbach et al. AUTOIMMUNITY REVIEWS
- Diagnostic and Therapeutic Differences Between Immune Checkpoint Inhibitor‐Induced and Idiopathic Bullous Pemphigoid: A Cross‐Sectional Study
- (2020) G.E. Molina et al. BRITISH JOURNAL OF DERMATOLOGY
- Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
- (2020) Adrienne M. Luoma et al. CELL
- The impact of beta blockers on survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors
- (2020) Michael S. Oh et al. Clinical Lung Cancer
- Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand
- (2020) James Randall Patrinely et al. EUROPEAN JOURNAL OF CANCER
- Association of Impaired Spermatogenesis With the Use of Immune Checkpoint Inhibitors in Patients With Metastatic Melanoma
- (2020) Jason M. Scovell et al. JAMA Oncology
- Immune checkpoint inhibitor-associated celiac disease
- (2020) Yousef Badran et al. Journal for ImmunoTherapy of Cancer
- Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis
- (2020) Michael Li et al. CANCER
- Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in Large Arteries
- (2020) Raffaella Calabretta et al. CIRCULATION
- Association Between Immune Checkpoint Inhibitors with Cardiovascular Events and Atherosclerotic Plaque
- (2020) Zsofia D. Drobni et al. CIRCULATION
- Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153
- (2020) David M. Waterhouse et al. JOURNAL OF CLINICAL ONCOLOGY
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- (2020) Alexander M. M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
- (2020) Paolo A Ascierto et al. LANCET ONCOLOGY
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- (2020) Reinhard Dummer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes
- (2020) Eliot R. Dow et al. OCULAR IMMUNOLOGY AND INFLAMMATION
- The potential for immune checkpoint modulators in cerebrovascular injury and inflammation
- (2020) Jennifer E. Kim et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Spectrum and impact of checkpoint inhibitor-induced irAEs
- (2020) Laura C. Cappelli et al. Nature Reviews Rheumatology
- A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention
- (2020) Spencer C Wei et al. Cancer Discovery
- Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry
- (2020) Michel M. Sun et al. OPHTHALMOLOGY
- A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
- (2019) Alessio Cortellini et al. Journal for ImmunoTherapy of Cancer
- Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review
- (2019) Hiroko Kadota et al. Current Rheumatology Reports
- PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model
- (2019) Neta Rosenzweig et al. Nature Communications
- Hematologic Complications of Immune Checkpoint Inhibitors
- (2019) Elizabeth J. Davis et al. ONCOLOGIST
- A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors
- (2019) Jeroen de Filette et al. HORMONE AND METABOLIC RESEARCH
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
- (2019) Y J L Jansen et al. ANNALS OF ONCOLOGY
- Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.
- (2019) Daniel H. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
- (2019) Blake M. Warner et al. ONCOLOGIST
- The impact of high-dose glucocorticoids on the outcome of immune checkpoint inhibitor-related thyroid disorders
- (2019) Chanjuan Ma et al. Cancer Immunology Research
- Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer
- (2019) Fiamma Berner et al. JAMA Oncology
- Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma
- (2019) Henry T. Quach et al. JAMA Oncology
- Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
- (2019) Douglas B. Johnson et al. Journal for ImmunoTherapy of Cancer
- Myocarditis in the Setting of Cancer Therapeutics
- (2019) Marc P. Bonaca et al. CIRCULATION
- Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes
- (2019) Venessa H M Tsang et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
- (2019) Hamzah Abu-Sbeih et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
- (2019) Edward B. Garon et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment Outcomes of Immune-Related Cutaneous Adverse Events
- (2019) Gregory S. Phillips et al. JOURNAL OF CLINICAL ONCOLOGY
- A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
- (2019) Douglas B. Johnson et al. NATURE MEDICINE
- Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
- (2019) Khashayar Esfahani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
- (2019) Joe-Elie Salem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
- (2019) Suzanne L. Topalian et al. JAMA Oncology
- THYROID DYSFUNCTION, RECOVERY, AND PROGNOSIS IN MELANOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A RETROSPECTIVE REVIEW.
- (2019) Mazen Al Mushref et al. Endocrine Practice
- Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis
- (2019) Alexander Faje et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
- (2019) Divyanshu Dubey et al. NEUROLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–PD-1–Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients
- (2019) Douglas B. Johnson et al. Cancer Immunology Research
- Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
- (2019) Yousef R. Badran et al. Journal for ImmunoTherapy of Cancer
- Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations
- (2019) Amalia Anastasopoulou et al. Journal for ImmunoTherapy of Cancer
- CD8+T CELLS REGULATE LIVER INJURY IN OBESITY-RELATED NONALCOHOLIC FATTY LIVER DISEASE
- (2019) Denitra A Breuer et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Health care utilization and steroid‐refractory toxicities from immune checkpoint inhibitors
- (2019) Laura X. Wang et al. CANCER
- Single-cell immune landscape of human atherosclerotic plaques
- (2019) Dawn M. Fernandez et al. NATURE MEDICINE
- The Impact of Nonsteroidal Anti‐Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti‐PD‐1 Therapy in Advanced Melanoma
- (2019) Daniel Y. Wang et al. ONCOLOGIST
- Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management
- (2019) Chandra K. Ala et al. Current Cardiology Reports
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
- (2019) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
- (2019) Hamzah Abu-Sbeih et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database
- (2019) Julie Garon-Czmil et al. Scientific Reports
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Early B cell changes predict autoimmunity following combination immune checkpoint blockade
- (2018) Rituparna Das et al. JOURNAL OF CLINICAL INVESTIGATION
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- (2018) Caroline Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
- (2018) Syed S. Mahmood et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
- (2018) Jennifer L McQuade et al. LANCET ONCOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen
- (2018) Laura C. Cappelli et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC
- (2018) Fernando Costa Santini et al. Cancer Immunology Research
- PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production
- (2018) Lindsay J. Celada et al. Science Translational Medicine
- Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
- (2018) Priyanka C. Iyer et al. THYROID
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
- (2018) Jordan J. Wright et al. DIABETES CARE
- Immune Checkpoint Inhibitor Toxicity in 2018
- (2018) Douglas B. Johnson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
- (2018) Joe-Elie Salem et al. LANCET ONCOLOGY
- Diagnosis and Management of Immune Checkpoint Inhibitor‐Associated Neurologic Toxicity: Illustrative Case and Review of the Literature
- (2018) Kerry L. Reynolds et al. ONCOLOGIST
- Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study
- (2018) Yael Eshet et al. Cancer Immunology Research
- Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients
- (2017) Valentine Heidelberger et al. INVESTIGATIONAL NEW DRUGS
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Chromatin states define tumour-specific T cell dysfunction and reprogramming
- (2017) Mary Philip et al. NATURE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
- (2017) Jarushka Naidoo et al. ONCOLOGIST
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
- (2017) Hyunju Lee et al. Cancer Immunology Research
- Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
- (2017) Chipman RG Stroud et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
- (2017) Eileen Shiuan et al. Journal for ImmunoTherapy of Cancer
- Smoldering myocarditis following immune checkpoint blockade
- (2017) Timothy G. Norwood et al. Journal for ImmunoTherapy of Cancer
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- (2016) A. M. Menzies et al. ANNALS OF ONCOLOGY
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
- (2016) Laura C Cappelli et al. ANNALS OF THE RHEUMATIC DISEASES
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Pregnancy promotes tolerance to future offspring by programming selective dysfunction in long-lived maternal T cells
- (2016) Brendan M. Barton et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Combinatorial approach to cancer immunotherapy: strength in numbers
- (2016) Anna E. Vilgelm et al. JOURNAL OF LEUKOCYTE BIOLOGY
- PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease
- (2016) Kuti Baruch et al. NATURE MEDICINE
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Toxic Effects of Targeted Cancer Therapies
- (2016) Javid J. Moslehi NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
- (2016) Krista Dubin et al. Nature Communications
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
- (2015) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation
- (2015) Sheetal Bodhankar et al. STROKE
- Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
- (2015) Douglas B. Johnson et al. Cancer Immunology Research
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Opportunistic infections in patients treated with immunotherapy for cancer
- (2014) Chrisann Kyi et al. Journal for ImmunoTherapy of Cancer
- The Cardiovascular Perils of Cancer Survivorship
- (2013) Javid Moslehi NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives
- (2013) Steven M. Bair et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Programmed Death-1 Pathway Limits Central Nervous System Inflammation and Neurologic Deficits in Murine Experimental Stroke
- (2011) Xuefang Ren et al. STROKE
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
- (2010) Ted A. Gooley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
- (2008) Jean-Pierre Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started